Skip to content
Parakho

Bajaj Healthcare Ltd

NSE BAJAJHCAREBSE 539872bajajhealth.com

Q1 FY27, unaudited

Revenue
₹165.63 Cr
Profit after tax
₹13.70 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations165.63+11.28%611.03
Other income0.81−7.55%7.13
Total income166.44+11.17%618.17
Employee benefit expense17.47+21.70%62.75
Finance costs6.09+16.56%22.23
Depreciation & amortisation7.01+24.44%27.55
Total expenses149.98+10.94%556.00
Profit before tax16.46+13.31%28.92
Tax expense2.57+9.11%7.61
Profit after tax13.70+15.75%15.77
Total comprehensive income13.92+15.82%16.38
Earnings per share
Earnings per share, basic₹4.07₹4.98
Earnings per share, diluted₹4.06₹4.97

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Bajaj Healthcare reported Q1 FY27 revenue of Rs 165.6 crore, up 11.3% year-on-year, with EBITDA margin expanding to 17.8%. Management described progress on new manufacturing facilities for peptides and oncology APIs, first-mover regulatory approvals in CNS therapy, and a reduction in debt-to-equity ratio. Domestic API business grew 27% year-on-year and was highlighted as the key growth driver for the quarter.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 34 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 21 Aug 2026.